Esperion Therapeutics (ESPR) Other financing activities (2020 - 2025)

Esperion Therapeutics has reported Other financing activities for 6 years, with the latest figure at $7.5 million in Q4 2025.

• For the quarter ending Q4 2025, Other financing activities changed N/A year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (up 7.79% YoY), and the FY2025 full-year result was $7.5 million, down 22.09% from the prior year.
• Other financing activities for Q4 2025 stood at $7.5 million, up from $400000.0 in the prior quarter.
• The five-year high for Other financing activities was $7.5 million in Q1 2025, with the low at -$438000.0 in Q4 2022.
• Historically, Other financing activities has averaged $1.5 million across 5 years, with a median of $400000.0 in 2023.
• Annual changes were most pronounced in 2022 — Other financing activities jumped 338.0% — and 2023, when it sank 50.0%.
• Esperion Therapeutics' Other financing activities stood at $500000.0 in 2021, then tumbled by 187.6% to -$438000.0 in 2022, then soared by 191.32% to $400000.0 in 2023, then slumped by 50.0% to $200000.0 in 2024, then soared by 3650.0% to $7.5 million in 2025.
• The last three Other financing activities figures came in at $7.5 million (Q4 2025), $400000.0 (Q3 2025), and $400000.0 (Q2 2025), per Business Quant data.